The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,774.00
Ask: 1,774.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Risk-Off Mood As Weak UK Services Adds To Worry

Wed, 05th Dec 2018 12:12

LONDON (Alliance News) - London stocks slid on Wednesday as risk-off sentiment replaced the more upbeat mood at start of the week, with markets in the US and Asia slumping overnight amid global trade and economic growth concerns.Meanwhile, buyers of the pound weren't fazed by disappointing data on the UK's crucial services industry, which suggested that Brexit anxiety has weighed on business activity and sentiment in November."Given the scale of the sell-off in the US, many would have expected a very bleak day for European markets. But with the US out of the picture today, things are quieter. Besides, the FTSE and others had not joined in the big rally last week following Jerome Powell's speech, held back by a stronger pound and euro as the dollar dropped," said IG chief market analyst Chris Beauchamp.He added: "However, indices on this side of the Atlantic are now back to the lows of November - while this might hold, the outlook does not look particularly encouraging."The FTSE 100 index at midday was down 81.57 points, or 1.2%, at 6,941.19. The FTSE 250, however, was up 0.1%, or 17.88 points, at 18,347.52. The AIM All-Share was 0.9% lower at 913.63.The Cboe UK 100 was down 1.3% at 11,778.28, while the Cboe UK 250 was up 0.2% at 16,415.02. The Cboe UK Small Companies was down 0.6% at 11,333.37.In mainland Europe at midday, the CAC 40 index in Paris and the DAX 30 in Frankfurt were down 0.9% and 0.8%, respectively. Markets in the US are closed on Wednesday for the funeral of former US President George HW Bush.The pound was broadly unchanged at USD1.2742 compared to USD1.2732 late Tuesday despite the weak print on the UK's dominant services sector.The closely watched IHS Markit/CIPS UK services Purchasing Managers' Index showed a reading of 50.4 in November, falling dangerously close to the no-change mark of 50 after October's level of 52.2. The PMI figure had been expected to be unchanged from October. November saw the worst performance since July 2016, when business sagged following the result of the referendum on Britain's membership of the EU. Excluding July 2016, it was also the worst performance since February 2013.The survey suggests that Brexit anxiety has weighed on business activity and sentiment with companies more risk averse when making spending and investment plans following reports that Britain could crash out of the EU with no deal."The bottom line is that fourth quarter growth is likely to be noticeably lower than in the third, and as we noted on Monday, we have our doubts that this will be heavily offset by pre-Brexit inventory building. While recent Bank of England commentary has made it clear that policymakers would like to resume tightening fairly soon given the stronger wage growth backdrop, we don't expect a rate hike before May 2019 - with a clear risk that this could be pushed back later into 2019," commented James Smith, developed markets economist at ING.Meanwhile, Markit's composite PMI for the eurozone fell to 52.7 in November from October's 53.1.In other data from the currency bloc, eurozone retail sales grew in October after decreasing in the previous month. Retail sales grew 0.3% from September, when they fell 0.5%, after the stagnation reported earlier was revised. Economists had forecast a 0.2% increase for October. Among the fallers in the FTSE 100 on Wednesday was rental equipment firm Ashtead, down 4.4% as investors fretted over a possible slowdown in US economic growth. Of Ashtead's GBP3.71 billion in revenue generated in the financial year ended April 30, US unit Sunbelt contributed a whopping GBP3.10 billion, or 84%."The firm, which was (and arguably remains) such a good way to play US economic growth, is the first port of call when worries about said growth are dominating minds. But with Monday's ISM manufacturing PMI near the highs for a decade, perhaps investors are overly concerned," commented IG's Beauchamp. Hargreaves Lansdown was down 4.0% after Morgan Stanley late Tuesday downgraded the fund supermarket to Underweight from Equal Weight. GlaxoSmithKline also was knocked by a broker's opinion, falling 3.3% after Barclays cut the pharma giant to Equal Weight from Overweight.Meanwhile, fellow drugmaker Shire was up 2.7% after after Takeda Pharmaceutical shareholders approved the acquisition of the Irish drugmaker.The acquisition remains subject to approval by Shire shareholders at a meeting expected to be held later Wednesday, and it is expected that completion of the acquisition will take place on January 8.In the FTSE 250, Stagecoach was among the best performers as it gained 11% on a set of better-than-expected interim results, despite swinging to a loss. Adjusted pretax profit fell to GBP87.0 million in the half-year to October 27 from GBP96.7 million a year before, as the company swung to a statutory pretax loss of GBP22.6 million from a GBP96.7 million profit reported for the same period a year earlier. Operating profit for UK Rail was highlighted as being ahead of forecasts, despite profit for the unit falling 47% to GBP11.5 million from GBP21.7 million a year ago. The company said the fall reflected the expiry of the South West Trains franchise."The group is focused on making further progress in the second half of the year and we have increased our expectation of full-year adjusted earnings per share to reflect the above-forecast rail earnings in the first half of the year," said Chief Executive Martin Griffiths.Thomas Cook was the top gainer in the FTSE 250, shares jumping 36% as the travel agent moves on from a miserable time last week. Thomas Cook issued a profit warning on Tuesday last week just days before the release of its annual results as it also suspended the payment of a final dividend. The company also looks set to be ejected from the FTSE 250 in the quarterly index review, the results of which will be released after the market close on Wednesday. Among other possible index changes, Royal Mail is facing demotion from the FTSE 100 to be replaced by insurer Hiscox. Aston Martin and Funding Circle are among the stocks up for membership in the FTSE 250.Despite Thomas Cook's significant gain on Wednesday, the stock remains 74% lower since the start of 2018.

More News
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.